Rather than attacking cancer cells directly, new cell-model research probes weaknesses in pancreatic cancer’s interactions with other cells to obtain nutrients needed for tumor growth.
Demsky joined the University of Michigan Rogel Cancer Center communications team in 2019. Prior to that he served as director of communications for the University of Michigan's Life Sciences Institute and science editor for Medicine at Michigan Magazine.
In cell and mouse models, miR181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.
A U-M review found national Choosing Wisely recommendations to reduce overtreatment in early stage breast cancer weren’t consistently followed.
The protein Argonaute 2 was found to be critical to the progression from benign lesions into pancreatic cancer, suggesting a therapeutic opportunity.
The University of Michigan’s OncCOVID app draws on global cancer and coronavirus data to create an individualized mortality risk assessment for receiving immediate versus delayed cancer treatment.